



MEDICAL TIPS

BLUGLIP-M TABLETS

Issue IV, No. 14, 2022

Clinical diagnosis and safety of vildagliptin versus glimepiride with metformin over patients of type-2 diabetes mellitus

Yadav P et al. Int J of Pharmaceutical Sciences & Research 2022; 13(1): 384-391.

- A clinical study on 160 patients was conducted to compare the efficacy of vildagliptin (50mg) and glimepiride (2mg) when added to metformin (500mg) on T2DM patients.
- The patients with a baseline HbA1c of 7.0-10.5% were divided into two groups to receive either 50 mg of vildagliptin with 500 mg of metformin or 2 mg of glimepiride with 500 mg of metformin twice daily for a duration of 34 weeks.
- The vildagliptin group showed a greater reduction in HbA1c, fasting plasma glucose and post prandial plasma glucose as compared to the glimepiride group.
- The body weight reduced with vildagliptin whereas increased with glimepiride.

Vildagliptin group results were found to be potential treatment with more benefits with comparison to glimepiride and was good for pancreatic beta cell, with lower risk of hypoglycemia comparison to glimepiride.

